16 September 2026 editorial review · Item
PIpepTolDC tolerogenic dendritic-cell vaccine: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: PIpepTolDC Phase 1 has actual enrollment six, primary completion in 2024 and active follow-up through an estimated 2026 completion. No posted results; personalized manufacturing and safety-first design remain limits.
- Registry NCT04590872: ACTIVE_NOT_RECRUITING; updated 2026-04-22; enrollment 6 (ACTUAL); primary completion 2024-06-03 (ACTUAL); results not posted in retrieved record.